Patent ID: 8076362

Claim:
A solid dosage form for administration comprising an amount ranging from 20 mg to less than 500 mg of crystal modification A of the compound 1-(2,6-difluorobenzyl)-1H-1,2,3-triazole-4-carboxamide and a solid pharmaceutically-acceptable carrier, wherein crystal modification A is characterized by characteristic lines with interplanar spacings (d values) of 10.5 Å, 5.14 Å, 4.84 Å, 4.55 Å, 4.34 Å, 4.07 Å, 3.51 Å, 3.48 Å, 3.25 Å, 3.19 Å, 3.15 Å, 3.07 Å, and 2.81 Å, determined by means of an X-ray powder pattern.